|
|
| Firm |
Analyst |
| Barclays Capital
|
Jim Birchenough, M.D. |
| BMO Capital Markets
|
Jason Zhang, Ph.D. |
| Canaccord Adams
|
Adam Cutler |
| Cowen & Co.
|
Phil Nadeau, Ph.D. |
| CRT Capital Group
|
Leah A. Hartman |
| Davenport & Company
|
Joel M. Ray, CFA |
| Hapoalim Securities
|
Jon LeCroy, M.D. |
| Jefferies & Company
|
Thomas Wei |
| JMP Securities
|
Jason N. Butler, Ph.D. |
| JPMorgan
|
Cory Kasimov |
| Lazard Capital Markets
|
William Tanner, Ph.D. |
| Leerink Swann and Co.
|
Steve Y. Yoo |
| Needham & Company
|
Alan Carr |
| Oppenheimer & Co.
|
Bret Holley, Ph.D. |
| Piper Jaffray
|
Edward A. Tenthoff |
| Rodman and Renshaw
|
Elemer Piros, Ph.D. |
| Summer Street Research Partners
|
Carol Werther |
| UBS
|
Jeff Elliott, Ph.D. |
| Wells Fargo Securities
|
Aaron S. Reames |
Arena Pharmaceuticals, Inc. is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Arena Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Arena Pharmaceuticals, Inc. or its management. Arena Pharmaceuticals, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
(Note: This page was last updated on: June 16, 2010.)
|
